PSIL:NYE-AdvisorShares Psychedelics ETF (USD)

ETF | Others |

Last Closing

USD 7.85

Change

0.00 (0.00)%

Market Cap

USD 4.53M

Volume

2.20K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

ETFs Containing PSIL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 464.75% 99% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 464.75% 99% N/A 96% N/A
Trailing 12 Months  
Capital Gain 387.58% 99% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 387.58% 99% N/A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -29.93% N/A N/A 1% F
Dividend Return -29.87% N/A N/A 1% F
Total Return 0.06% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 24.31% N/A N/A 43% F
Risk Adjusted Return -122.87% N/A N/A N/A F
Market Capitalization 4.53M 10% F 3% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.